Ağır Kombine İmmün Yetmzelikte Hematopoetik Kök Hücre Nakli; Tek Merkez Tecrübesi

Year 2022, Volume: 12 Issue: 1, 24 - 28, 18.03.2022

Serdar Nepesov , Yöntem Yaman , Murat Elli Nihan Bayram , Kürşat Özdilli , Ayça Kıykım Sema Anak

https://doi.org/10.26650/experimed.2022.1077058

Abstract

Amaç: Bu çalışmada amaçlanan Ağır kombine immün yetmezlik (AKİY) tanısıyla kemik iliği uygulanan hastalarda sağkalım ve mortaliteyi etkileyen faktörleri belirlemek ve tek merkez deneyimlerimizi paylaşmaktır.
Gereç ve Yöntemler: İstanbul Medipol Üniversitesi çocuk kemik iliği nakil ünitesinde Ocak 2014-Ocak 2021 tarihleri arasında AKİY tanısıyla kemik iliği nakli yapılan olguların dosya verileri incelendi. Olguların demografik ve klinik nitelikleri, uygulanan tedavi rejimleri, verici kaynağı, nakil tipi, nakil öncesi ve sonrası enfeksiyonlar, nakil sonrası gelişen komplikasyonlar irdelendi.
Bulgular: Hematopoetik kök hücre nakli (HKHN) uygulanan 15 hastanın 5 (%33)’i kız, 10 (%67)’u erkek idi. Ortalama tanı yaşı 3 ay (1 ile 6 ay aralığında) nakil yaşı 6 ay (3 ile 10 ay aralığında) olup, tanı ile nakil süresi ortalama 3 ay. Ortalama izlem süresi 23 ay. Olguların 13 (%87)‘ünde akraba evliliği, 8(%53)’ inde kardeş ölüm öyküsü vardı. Donör olarak 6 ‘sına kardeş, 5' ine akraba dışı, 5 hastaya haploid nakil uygulandı. 4 (%27) hasta nakilin ilk 100 gününde kaybedildi. İzlemde olan hastaların ortanca takip süreleri 23 ay (9-61 ay). Hastaların genel sağkalım olasılığı %73 olarak hesaplandı.
Çıkarımlar: AKİY pediyatrik acil olarak değerlendirilmelidir. Tanı ve tedavisi geç kalındığında hastada ağır organ hasarı gelişmekte veya hasta erken dönemde ciddi enfeksiyonlardan kaybedilmektedir. HKHN küratif tedavi seçeneği olup, tanısı kesinleşen hastalara en kısa zamanda tedavi başlanmalı ve uygun kemik iliği nakil merkezine yönlendirilmelidir.

Keywords

Ağır kombine immün yetmezlik, kemik iliği nakli, pediatri

Hematopoietic Stem Cell Transplantation in Patients with Severe Combined Immunodeficiency: A Single-Center Experience

Abstract

Objective: The aim of this study was to determine the factors affecting outcomes in patients who underwent hematopoietic stem cell transplantation (HSCT) with the diagnosis of severe combined immunodeficiency (SCID). Furthermore, our aim is to share our single-center experience of HSCT among SCID patients.

Materials and Methods: The data of patients who underwent HSCT with the diagnosis of SCID between January 2014 and January 2021 in the pediatric bone marrow transplant unit of Istanbul Medipol University were retrospectively analyzed. Demographic and clinical data, treatment regimens, donor source, type of transplantation, pre- and post-transplantation infections, and complications were evaluated.

Results: Among fifteen patients who underwent HSCT, 5 (33%) were female. The mean age at diagnosis was 3 months (1-6 months), and at transplantation 6 months (3-10 months). The mean time from diagnosis to transplantation was 3 months (2-9 months). There was a history of consanguineous marriage in thirteen (87%) and sibling death in eight (53%) cases. As donors, six (40%) were siblings and five (33%) were unrelated, while four (27%) patients underwent haploid transplantation. Four (27%) patients died during the first 100 days of transplantation. The median follow-up period was 23 months (9-61 months). Overall survival probability was calculated as 73%.

Conclusion: SCID should be considered as an emergency in pediatrics. Devastating complications, including severe organ damage, life-threatening infections, and even death, could appear in case of diagnostic delay. HSCT is a currently available curative treatment option. Subjects with a confirmed diagnosis should be referred to the appropriate bone marrow transplant center and treated as soon as possible.

Keywords

Bone marrow transplantation, children, severe combined immunodeficiency

References

• 1. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of prima-ry immunodeficiency. J Allergy Clin Immunol 2015; 136: 1186. [CrossRef] google scholar
• 2. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020; 40: 24. [CrossRef] google scholar
• 3. Kilic SS, Ozel M, Hafizoglu D, Karaca NE, Aksu G, Kutukculer N. The prevalences and patient characteristics of primary immunodefi-ciency diseases in Turkey-two centers study. J Clin Immunol 2013; 33(1): 74-83. [CrossRef] google scholar
• 4. Cowan MJ, Neven B, Cavazanna-Calvo M, Fischer A, Puck J. Hema-topoietic stem cell transplantation for severe combined immu-nodeficiency diseases. Biol Blood Marrow Transplant 2008; 14(1 Suppl 1): 73-5. [CrossRef] google scholar
• 5. Lankester AC, Albert MH, Booth C, Gennery AR, Güngör T, Hönig M, et al. EBMT/ESID inborn errors working party guidelines for he-matopoietic stem cell transplantation for inborn errors of immu-nity. Bone Marrow Transplant 2021; 56(9): 2052-62. [CrossRef] google scholar
• 6. Wahlstrom JT, Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Curr Pe-diatr Rep 2015; 3: 1. [CrossRef] google scholar
• 7. Miyamoto S, Umeda K, Kurata M, Yanagimachi M, Iguchi A, Sasaha-ra Y, et al. Hematopoietic cell transplantation for severe combined immunodeficiency patients: a Japanese retrospective study. J Clin Immunol 2021; 41(8): 1865-77. [CrossRef] google scholar
• 8. Neven B, Leroy S, Decaluwe H, Le Deist F, Picard C, Moshous D, et.al. Long-term outcome after hematopoietic stem cell trans-plantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009; 113(17): 4114-24. [CrossRef] google scholar
• 9. Muller SM, Ege M, Pottharst A, Schulz AS, Schwarz K, Friedrich W. Transplacentally acquired maternal T lymphocytes in severe com-bined immunodeficiency: a study of 121 patients. Blood 2001; 98: 1847-51. [CrossRef] google scholar
• 10. Lev A, Simon AJ, Trakhtenbrot L, Goldstein I, Nagar M, Stepensky P, et al. Characterizing T cells in SCID patients presenting with re-active or residual T lymphocytes. Clin Dev Immunol 2012; 2012: 261470. [CrossRef] google scholar
• 11. Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG, et al. Neonatal diagnosis of severe combined immunodeficien-cy leads to significantly improved survival outcome: the case for newborn screening. Blood 2011; 117: 3243. [CrossRef] google scholar
• 12. Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, et.al. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 2014; 133(2): 335-47. google scholar
• 13. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002; 99: 872. [CrossRef] google scholar
• 14. Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who re-ceived related donor bone marrow transplants without pretrans-plant chemotherapy or post-transplant GVHD prophylaxis. J Pedi-atr 2009; 155: 834. [CrossRef] google scholar
• 15. Dvorak CC, Hassan A, Slatter MA, Hönig M, Lankester AC, Buck-ley RH, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol 2014; 134: 935. [CrossRef] google scholar
• 16. King D, Davies GE, Gaspar HB, Veys PA. Improved survival after un-related donor bone marrow transplantation in children with pri-mary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005; 105(2): 879-85. [CrossRef] google scholar
• 17. Heimall J, Logan BR, Cowan MJ, Notarangelo LD, Griffith LM, Puck JM, et al. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. Blood 2017; 130: 2718. [CrossRef] google scholar
• 18. Brown LK, Clark I, Brown JR, Breuer J, Lowe DM.. Norovirus infec-tion in primary immune deficiency. Rev Med Virol 2017; 27: e1926. [CrossRef] google scholar
• 19. Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, Noroski LM, et al. Vaccine-acquired rotavirus in infants with severe com-bined immunodeficiency. N Engl J Med 2010; 362: 314. [CrossRef] google scholar
• 20. Canessa C, Romano F, Lippi F, Bianchi L, Kashef S, Rezaei N, et al. Bcgitis and vaccine-derived poliovirus infection in a patient with a novel deletion in RAG1 binding site. Int J Immunopathol Pharma-col 2013; 26: 511. [CrossRef] google scholar
• 21. Dvorak CC, Puck JM, TePas E. Hematopoietic cell transplantation for severe combined immunodeficiencies. (Available from [up-dated 06/02/2022.;cited2022January].https://www.uptodate. com/contents/search/hematopoietic-cell-transplantation-for-se-vere-combined-immunodeficienciese). google scholar